Imagine living in a state with the second highest rate of chlamydia and the third highest rate of congenital syphilis infections in the United States (U.S.) in 2018. Our first thought was how can this be, and our second thought was what can we do to overcome this? When we looked at the 2019 U.S. Cen...
The FDA recently approved the use of an extended-release injectable formulation of the integrase inhibitor cabotegravir (CAB) for preexposure prophylaxis (PrEP) for adults and adolescents at risk for HIV infection. After two initial intramuscular (IM) injections given 1 month apart, it is administer...
In December 2021, the U.S. Centers for Disease Control and Prevention issued thoroughly revised and updated PrEP guidelines. The guidelines include important new information on the use of oral PrEP (TDF/FTC and TAF/FTC) and recommendations on the use of injectable cabotegravir (CAB) as PrEP.
Key upda...
Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC) are the two most common bacterial sexually transmitted infections in the United States. The incidence of CT and GC have increased consistently since 2014, and current rates are at an all-time high. CT and GC infections are treatable with anti...
TANGO is a randomized open-label study in which subjects with virologic suppression on standard 3-drug TAF-based ART either switched to the 2-drug regimen of dolutegravir (DTG)/lamivudine (3TC) n = 369) or continued their baseline ART (n = 372). Previously published data showed no significant differ...
The FLAIR study evaluated the efficacy and safety of the long-acting injectable regimen of cabotegravir (CAB) + rilpivirine (RPV) in previously ART-naïve individuals who switched to CAB+RPV after viral suppression on a standard 3-drug oral regimen (dolutegravir [DTG]/ABC/3TC). At both 48 weeks (the...
Lenacapavir (LEN) is a novel investigational long-acting injectable ARV that is administered every 6 months by subcutaneous (SC) injection. It is an HIV-1 capsid inhibitor that acts at several points in the HIV life cycle. As a novel class, has full activity against viruses with resistance to the NR...
While sexually transmitted infections (STIs) affect individuals of all ages, STIs take a hefty toll on young adults with HIV in Washington, DC. Despite continual public health efforts to reduce the rate of new STI infections, adolescents and young adults persist as the majority of new STI diagnoses...
The AETC Program's new resource combines the most up-to-date, HIV screening, prevention, and care resources in one mobile app, to provide access to essential point-of-care information and expert clinical support with just one touch.
HIV Care Tools is for busy clinicians from novice-to-expert, clinic...
National Alliance of State & Territorial AIDS Directors' (NASTAD) Center for Innovation and Engagement (CIE)
As public health professionals, educators, and HIV care providers, it is imperative that we develop truly innovative approaches to address the health and social needs of communities and a...
The Native American Community Clinic (NACC) in Minneapolis has been highly successful in integrating HIV care into their Federally Qualified Health Center (FQHC). Minnesota has eleven sovereign American Indian (AI) nations1, and the Phillips neighborhood of Minneapolis (where NACC is located) has th...
Black men who have sex with men (BMSM) are more affected by HIV than any other group in the United States. In spite of recent incremental progress to reduce the rate of increase in new HIV infections, Black men continue to account for the largest proportion of new HIV diagnoses among MSM. Not only a...
At the onset of the COVID-19 pandemic, the Northeast/Caribbean (NECA) AIDS Education & Training Center (AETC) found itself in need of a massive shift in its training methods. Within a matter of days, we were faced with shifting all of our in-person learning sessions to an entirely virtual format...
A long-acting formulation of the investigational integrase inhibitor cabotegravir (CAB) is being studied as a single agent for HIV prevention. (CAB also has been studied, in combination with long-acting rilpivirine, as treatment for people with HIV, see Long-Acting Injectable ART: Cabotegravir + Ril...
Recommendations and Reports / July 24, 2020 / 69(6);1–8
Exposure to hepatitis viruses is a recognized occupational risk for health care personnel (HCP). This report establishes new U.S. Centers for Disease Control and Prevention (CDC) guidance that includes recommendations for a testing algorithm and...
In July 2020, the U.S. Food and Drug Administration approved fostemsavir (FTR) for treatment of people with multi-drug resistant HIV-1 whose current ARV regimen is failing because of resistance, intolerance, or safety issues. FTR is a novel attachment inhibitor that binds the HIV envelope glycoprote...
In 2018, initial results from the Tsepamo study of birth outcomes in Botswanan women treated with ART during pregnancy raised questions about the safety of dolutegravir (DTG) when given at the time of conception or very early in pregnancy. Specifically, an early interim analysis found a higher propo...
As the global battle to understand and eliminate the coronavirus continues, a new study published in the Journal of Dental Research demonstrates that testing of oropharyngeal secretions (OS) may reduce the number of false-negative results from nasal swab testing of patients who have seemingly recove...
I never thought my experience as a Black woman, nor my experience as a woman who enjoys sex, would combine in a way that could put me in jail. When I was diagnosed with HIV in 2003, I had a very limited understanding of what that meant with respect to accessing treatment, being virally suppressed, d...
In HIV prevention and care, rural communities are often left out of the mix. But the Oregon Health Authority, in partnership with the YTH (Youth Tech Health) Initiative at ETR, is engaging rural communities in taking charge of their HIV prevention and treatment via Oregon Reminders.
Oregon Reminders...
